高级检索
    康晓征, 闫万璞, 陈克能, 唐文芳. 厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较[J]. 循证医学, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
    引用本文: 康晓征, 闫万璞, 陈克能, 唐文芳. 厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较[J]. 循证医学, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
    shu
    KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
    Citation: KANG Xiao-zheng, YAN Wan-pu, CHEN Ke-neng, TANG Wen-fang. Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 30-33. DOI: 10.12019/j.issn.1671-5144.2019.01.009
    shu

    厄洛替尼与标准一线化疗作为新辅助治疗ⅢA-N2期EGFR突变阳性非小细胞肺癌患者的疗效比较

    Erlotinib Versus Standard First-Line Chemotherapy as Neoadjuvant Treatment for Stage ⅢA-N2 EGFR-Mutation Positive Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(10)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回